Aaron Y. Mochizuki, DO
- Pediatric Neuro-Oncologist, Division of Oncology
- Assistant Professor, UC Department of Pediatrics
- aaron.mochizuki@cchmc.org
- Board Certified
About
Biography
As a pediatric neuro-oncologist, I treat patients with brain tumors as well as other solid tumors. I seek to provide compassionate care to each person and their family.
The awe-inspiring children going through the most challenging circumstances and their incredible families who support them inspired me to pursue my career.
My research examines how brain tumor immune-cell populations change with therapy and how those changes can predict treatment response.
In my free time, I enjoy running, hiking and snowboarding.
MD: A.T. Still University, Mesa, AZ, 2013
Internship: University of Hawaii, Honolulu, HI, 2014
Residency: LAC+USC Medical Center, Los Angeles, CA, 2016
Fellowship: Pediatric Hematology/Oncology, UCLA, Los Angeles, CA, 2019
Fellowship: Pediatric Neuro-Oncology, Stanford University, Palo Alto, CA, 2021
Interests
Pediatric neuro-oncology; immunotherapy
Services and Specialties
Interests
Data science; tumor microenvironment
Research Areas
Additional Languages
SpanishLocations (2)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma. Nature Medicine. 2026.
Murine modeling of IDH-mutant 1p/19q-codeleted oligodendroglioma reveals genotype specific phenotypes. Neuro-Oncology. 2026.
Discordant neoplasms in monozygotic twins with a germline RECQL5 variant. Cancer Genetics. 2026; 306-307:232-236.
A frontal lobe mass in a 6-year-old girl. Brain Pathology. 2026; e70132.
ID #476 Increased Prevalence of Optic Nerve Hypoplasia in Neurofibromatosis Type 1. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.170.
ID #1002 Hematologic Toxicity during Proton Radiation: a Review of Weekly CBC Results at a Single Center. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.440.
ID #1028 A Retrospective Review Characterizing the Toxicities, Outcomes, and Molecular Characteristics of Adolescent and Young Adult Patients with Medulloblastoma. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.457.
ID #1015 A murine model system for IDH-mutant 1p/19q-codeleted oligodendroglioma. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.446.
MEK inhibitor-induced dropped head syndrome in pediatrics. Neuro-Oncology Pediatrics. 2026; 2(2):wuag024.
BIOM-88. LEPTOMENINGEAL METASTASIS IN THE INTERNAL AUDITORY CANAL AS A PREDICTOR OF OUTCOMES FOR CHILDREN WITH CENTRAL NERVOUS SYSTEM TUMORS. Neuro-Oncology. 2025; 27(Supplement_5):v45-v45.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 2026 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey